High-dose ε-aminocaproic acid versus aprotinin: Antifibrinolytic efficacy in first-time coronary operations

Annals of Thoracic Surgery

Volumn 65, Issue 3, 1998, Pages 667-673

  Eberle, Balthasar ^a   Mayer, Eckhard ^a   Hafner, Gerhard ^a   Heinermann, Jens ^a   Dahm, Manfred ^a   Prellwitz, Winfried ^a   Dick, Wolfgang ^a   Oelert, Hellmut ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTIPLASMIN; APROTININ; CARDIOPLEGIC AGENT; D DIMER; FIBRIN DEGRADATION PRODUCT; HEMOGLOBIN; HEPARIN; PLASMIN; PROTAMINE; ST THOMAS HOSPITAL SOLUTION; THROMBIN ANTITHROMBIN COMPLEX; HEMOSTATIC AGENT;

ADULT; AGED; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FIBRINOLYSIS; HEMATOCRIT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX DRAINAGE; TREATMENT OUTCOME; BLOOD TRANSFUSION; COMPARATIVE STUDY; DRUG EFFECT; HEART MUSCLE REVASCULARIZATION; PROSPECTIVE STUDY;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD COAGULATION; BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; FIBRINOLYSIS; HEMATOCRIT; HEMOSTATICS; MYOCARDIAL REVASCULARIZATION; PROSPECTIVE STUDIES;

EID: 0032011132     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(97)01424-0     Document Type: Article

References (19)

1. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 2:1987;1289-1291.
2. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg. 58:1994;1580-1588.
3. Hardy JF, Bélisle S. Natural and synthetic antifibrinolytics in adult cardiac surgery efficacy, effectiveness and efficiency . Can J Anaesth. 41:1994;1104-1112.
4. Penta de Peppo A, Pierri MD, Scafuri A, et al. Intraoperative antifibrinolysis and blood saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J. 22:1995;231-236.
5. Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs. tranexamic acid vs. epsilon aminocaproic acid. J Cardiovasc Surg Torino. 37:1996;401-407.
6. Trinh-duc P, Wintrebert P, Boulfroy D, Albat B, Thevenet A, Roquefeuil B. Efficacy of ε-amino-caproic acid versus high-dose aprotinin on intra- and postoperative blood loss in cardiac surgery. Ann Chir Thorac Cardio-vasc. 46:1992;677-683.
7. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. J Thorac Cardiovasc Surg. 108:1994;99-108.
8. Vander Salm TJ, Kaur S, Lancey RA, et al. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg. 112:1996;1098-1107.
9. Boldt J, Zickmann B, Czeke A, Herold C, Dapper F, Hempelmann G. Blood conservation techniques and platelet function in cardiac surgery. Anesthesiology. 75:1991;426-432.
10. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 29:1985;236-261.
11. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology. 73:1990;1119-1126.
12. Tabuchi N, Njo TL, Tigchelaar I, Huyzen RJ, Boonstra PW, van Oeveren W. Monitoring of anticoagulation in aprotinin-treated patients during heart operation. Ann Thorac Surg. 58:1994;774-777.
13. Feindt P, Seyfert UT, Volkmer I, Straub U, Gams E. Celite and kaolin produce different activated clotting times during cardiopulmonary bypass under aprotinin therapy. Thorac Cardiovasc Surg. 42:1994;218-221.
14. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass operations efficacy, safety, and influence on early saphenous vein graft patency . J Thorac Cardiovasc Surg. 107:1994;543-553.
15. Havel M, Grabenwöger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg. 107:1994;807-810.
16. Wendel HP, Heller W, Gallimore MJ. The effects of aprotinin on chromogenic peptide substrate and other assays for components of the coagulation, fibrinolysis and plasma kallikrein systems. Fibrinolysis. 8:1994;304-308.
17. Kennedy DJ, Gravlee GP. Pharmacologic manipulation of coagulation promotion of hemostasis . Lake CL, Moore RA. Blood: hemostasis, transfusion and alternatives in the perioperative period. 1995;139 Raven Press, New York.
18. Soslau G, Horrow J, Brodsky I. The effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol. 38:1991;113-119.
19. Blauhut B, Harringer W, Bettelheim P, Doran JE, Späth P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 108:1994;1083-1091.